Which hospitals offer Enfortumab treatment?

Enfortumab is the first antibody-conjugated drug targeting Nectin-4, which has become a new treatment option for patients with advanced urothelial cancer (bladder cancer) worldwide. With its original drug approved for marketing in China, domestic patients finally have the opportunity to receive this internationally cutting-edge innovative therapy locally. Due to the short time to market, the related application scope and distribution of medical institutions are common concerns of patients and family members.

Judging from the current situation, the use of venetuzumab is mainly concentrated in large national and provincial oncology hospitals and hospitals with new drug clinical application qualifications. These medical institutions often have dedicated multidisciplinary teams (MDTs) in urological oncology or comprehensive oncology departments that can develop plans based on the patient's specific situation. At present, some cancer hospitals and university-affiliated hospitals in first-tier cities may gradually carry out clinical applications of this drug. Some centers have also participated in international multi-center studies and accumulated rich experience for domestic patients.

In terms of therapeutic applications,Enfortumab is mainly used for patients with locally advanced or metastatic urothelial cancer who have failed immune checkpoint inhibitors and platinum-containing chemotherapy. Doctors will decide whether to use this drug based on a comprehensive evaluation of the patient's condition, previous treatment history, organ function and tolerance. Since it is an antibody-conjugated drug, the injection administration process needs to be carried out in a qualified hospital so that adverse reactions can be dealt with in a timely manner. Common side effects include rash, peripheral neuropathy, and elevated blood sugar, requiring close follow-up during treatment.

In terms of price, due to the short time the drug has been on the market in China, the public price system and medical insurance coverage have not yet been clarified, which has also led to differences in accessibility in different regions. Some hospitals may currently offer medications through patient assistance programs or corporate support channels to help reduce patient burden.

Reference: https://www.padcev.com/